No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice

Erika Choi; Craig Branch; Min Hui Cui; Karina Yazdanbakhsh; Narla Mohandas; Henny H. Billett; Patricia A. Shi

doi:10.1016/j.bcmd.2015.12.008

No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice

Erika Choi, Craig Branch, Min Hui Cui, Karina Yazdanbakhsh, Narla Mohandas, Henny H. Billett, Patricia A. Shi

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.

Original language	English (US)
Pages (from-to)	67-70
Number of pages	4
Journal	Blood Cells, Molecules, and Diseases
Volume	57
DOIs	https://doi.org/10.1016/j.bcmd.2015.12.008
State	Published - Mar 1 2016

Keywords

Endothelial cell activation
Hematopoietic progenitor cell mobilization
Neutrophil activation
Platelet activation
Plerixafor
Sickle cell disease

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Hematology
Cell Biology

Access to Document

10.1016/j.bcmd.2015.12.008

Cite this

@article{0df406eddb9943d8975c0d486808a24f,

title = "No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice",

abstract = "Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.",

keywords = "Endothelial cell activation, Hematopoietic progenitor cell mobilization, Neutrophil activation, Platelet activation, Plerixafor, Sickle cell disease",

author = "Erika Choi and Craig Branch and Cui, {Min Hui} and Karina Yazdanbakhsh and Narla Mohandas and Billett, {Henny H.} and Shi, {Patricia A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.bcmd.2015.12.008",

language = "English (US)",

volume = "57",

pages = "67--70",

journal = "Blood Cells, Molecules, and Diseases",

issn = "1079-9796",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice

AU - Choi, Erika

AU - Branch, Craig

AU - Cui, Min Hui

AU - Yazdanbakhsh, Karina

AU - Mohandas, Narla

AU - Billett, Henny H.

AU - Shi, Patricia A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.

AB - Gene therapy for sickle cell disease is currently in active trials. Collecting hematopoietic progenitor cells safely and effectively is challenging, however, because granulocyte colony stimulating factor, the drug used most commonly for mobilization, can cause life-threatening vaso-occlusion in patients with sickle cell disease, and bone marrow harvest requires general anesthesia and multiple hip bone punctures. Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma. In support of a clinical trial in patients with sickle cell disease of plerixafor mobilization (NCT02193191), we administered plerixafor to sickle cell mice and found that it mobilizes hematopoietic progenitor cells without evidence of concomitant cell activation or brain vaso-occlusion.

KW - Endothelial cell activation

KW - Hematopoietic progenitor cell mobilization

KW - Neutrophil activation

KW - Platelet activation

KW - Plerixafor

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84959186003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959186003&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2015.12.008

DO - 10.1016/j.bcmd.2015.12.008

M3 - Article

C2 - 26852658

AN - SCOPUS:84959186003

SN - 1079-9796

VL - 57

SP - 67

EP - 70

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

ER -

No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this